Role of exclusive chemotherapy as first line treatment in oligodendroglioma

Journal of Neuro-Oncology

Volumn 85, Issue 3, 2007, Pages 319-328

  Sunyach, Marie Pierre ^a   Jouvet, Anne ^b   Perol, David ^a   Jouanneau, Emmanuel ^b   Guyotat, Jacques ^b   Gignoux, Laurence ^a   Carrie, Christian ^a   Frappaz, Didier ^a  

^a CENTRE LÉON BÉRARD   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Chemotherapy; Oligodendrogiloma; Radiotherapy

Indexed keywords

CARMUSTINE; FOTEMUSTINE; LOMUSTINE; MANNITOL; PROCARBAZINE; STEROID; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EDEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEUROSURGERY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADULT; AGED; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 36348978689     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9422-3     Document Type: Article

References (79)

1. Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S et al (2003) Summary version of the standards, options and recommendations for the management of adult patients with intracranial glioma (2002). Br J Cancer 89(Suppl 1):S73-S83
2. Andersen AP (1978) Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 17(6):475-484
3. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R et al (1981) Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4):649-652
4. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, Anderson H, Borgstrom S, Brun A et al (1991) A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 68(1):22-29
5. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49(3):333-343
6. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303(23):1323-1329
7. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8):2585-2597
8. Stewart LA (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311):1011-1018
9. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O et al (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organization for research and treatment of cancer study 22845 with the medical research council study BRO4: An interim analysis. Int J Radiat Oncol Biol Phys 52(2):316-324
10. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG et al (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36(3):549-556
11. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R et al (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a north central cancer treatment group/radiation therapy oncology group/eastern cooperative oncology group study. J Clin Oncol 20(9):2267-2276
12. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF et al (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of radiation therapy oncology group 83-02. Int J Radiat Oncol Biol Phys 38(5):911-914
13. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473-1479
14. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3):636-645
15. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J et al (1994) Chemotherapy for anaplastic oligodendroglioma. National cancer institute of Canada clinical trials group. J Clin Oncol 12(10):2013-2021
16. Cairncross JG (1994) Aggressive oligodendroglioma: A chemosensitive tumor. Recent Results Cancer Res 135:127-133
17. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X et al (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19(9):2449-2455
18. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133-3138
19. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1):203-207
20. Paleologos NA, Macdonald DR, Vick NA, Cairncross JG (1999) Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53(5):1141-1143
21. Soffietti R, Ruda R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43(5):1066-1073
22. Stege EM, Kros JM, de Bruin HG, Enting RH, van H, I, Looijenga LH et al (2005) Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103(4):802-809
23. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO et al (2006) Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist 11(2):165-180
24. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: A clinical efficacy trial. J Neurooncol 79(2):153-157
25. Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A et al (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63(5):904-906
26. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24(18):2707-2714
27. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24(18):2715-2722
28. Brown PD, Buckner JC, O'Fallon JR, Iturria NL, Brown CA, O'Neill BP et al (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21(13):2519-2524
29. Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH et al (1998) Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC radiotherapy co-operative group. Eur J Cancer 34(12):1902-1909
30. Torres IJ, Mundt AJ, Sweeney PJ, Llanes-Macy S, Dunaway L, Castillo M et al (2003) A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 60(7):1113-1118
31. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280
32. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
33. Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc Ser B 34:187-202
34. Burger PC (1995) Revising the world health organization (WHO) blue book - 'Histological typing of tumours of the central nervous system'. J Neurooncol 24(1):3-7
35. Hamlat A, Saikali S, Chaperon J, Le Calve M, Gedouin D, Ben Hassel M et al (2005) Oligodendroglioma: Clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus 19(5):E15
36. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958-1984). Cancer 71(12):4002-4006
37. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: The Mayo clinic experience. J Neurosurg 76(3):428-434
38. Hamlat A, Saikali S, Chaperon J, Le Calve M, Gedouin D, Ben Hassel M et al (2005) Oligodendroglioma: Clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus 19(5):E15
39. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958-1984). Cancer 71(12):4002-4006
40. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: The Mayo clinic experience. J Neurosurg 76(3):428-434
41. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up. Neurooncology 8(2):183-188
42. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958-1984). Cancer 71(12):4002-4006
43. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: The Mayo clinic experience. J Neurosurg 76(3):428-434
44. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35(6):1018-1034
45. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567-573
46. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35(6):1018-1034
47. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567-573
48. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35(6):1018-1034
49. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567-573
50. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J et al (1994) Chemotherapy for anaplastic oligodendroglioma. National cancer institute of Canada clinical trials group. J Clin Oncol 12(10):2013-2021
51. Macdonald DR, Gaspar LE, Cairncross JG (1990) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27(5):573-574
52. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24(18):2707-2714
53. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B et al (2004) Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14(2):121-130
54. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO et al (2001) Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7(4):839-845
55. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3):636-645
56. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24(18):2715-2722
57. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: A clinical efficacy trial. J Neurooncol 79(2):153-157
58. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M et al (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European organization for research and treatment of cancer brain tumor group study 26971. J Clin Oncol 21(13):2525-2528
59. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X et al (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19(9):2449-2455
60. van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC brain tumor group phase II study 26972. Ann Oncol 14(4):599-602
61. van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC brain tumor group phase II study 26972. Ann Oncol 14(4):599-602
62. Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A et al (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63(5):904-906
63. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473-2476
64. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1):203-207
65. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up. Neurooncology 8(2):183-188
66. Allam A, Radwi A, El Weshi A, Hassounah M (2000) Oligodendroglioma: An analysis of prognostic factors and treatment results. Am J Clin Oncol 23(2):170-175
67. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567-573
68. Nijjar TS, Simpson WJ, Gadalla T, McCartney M (1993) Oligodendroglioma. The princess margaret hospital experience (1958-1984). Cancer 71(12):4002-4006
69. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A (1994) Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35(6):1018-1034
70. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T et al (1987) Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67(2):224-230
71. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: The Mayo clinic experience. J Neurosurg 76(3):428-434
72. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: The Mayo clinic experience. J Neurosurg 76(3):428-434
73. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS (1994) The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30(3):567-573
74. Allison RR, Schulsinger A, Vongtama V, Barry T, Shin KH (1997) Radiation and chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol Biol Phys 37(2):399-403
75. Kros JM, Pieterman H, van Eden CG, Avezaat CJ (1994) Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 34(6):959-966
76. Bullard DE, Rawlings CE III, Phillips B, Cox EB, Schold SC Jr, Burger P et al (1987) Oligodendroglioma. An analysis of the value of radiation therapy. Cancer 60(9):2179-2188
77. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO et al (2006) Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist 11(2):165-180
78. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O et al (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organization for research and treatment of cancer study 22845 with the medical research council study BRO4: An interim analysis. Int J Radiat Oncol Biol Phys 52(2):316-324
79. Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET et al (2002) A new graphic for quality adjusted life years (Q-TWiST) survival analysis: The Q-TWiST plot. Qual Life Res 11(1):37-45